

Brand Name: ASTRAPAN 40

Composition: Pantoprazole for injection IP.

Dosage Form: Injection

Category: Proton Pump Inhibitor (PPI)

Packaging Type: Vial+ Wfi.

Packaging: 40 mg

Brief Product Introduction:

ASTRAPAN 40 Injection is a sterile injectable formulation of **Pantoprazole 40 mg**, manufactured by **AstraEureka Pharmaceutical**, a leading manufacturer of Pantoprazole-based compositions. Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion by irreversibly blocking the H⁺/K⁺ ATPase enzyme in the stomach lining. ASTRAPAN 40 is used in conditions such as gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, erosive esophagitis, and gastric or duodenal ulcers where intravenous acid suppression is essential. This injection is especially suited for patients unable to take oral medication or in emergency care settings. Its rapid onset of action offers fast relief from acid-related symptoms and protects gastric mucosa. Available in a 40 mg sterile vial for intravenous administration, ASTRAPAN 40 ensures precise dosing and dependable efficacy.

Composition:

Each vial contains

Pantoprazole Sodium (Sterile) IP

equivalent to Anhydrous Pantoprazole.....40 mg

Key Benefits:

1. Rapid acid suppression in critical care.
2. Effective in managing GERD and peptic ulcers.
3. Suitable for patients unable to take oral medication.
4. Reduces gastric acidity during surgery or ICU stay.
5. Safe and well-tolerated.

Indications:

1. Gastroesophageal reflux disease (GERD).
2. Erosive esophagitis.
3. Peptic ulcers.
4. Zollinger-Ellison syndrome.
5. Prophylaxis for stress ulcers in critically ill patients.

Directions for Use:

1. Reconstitute with appropriate diluent as per label instructions.
2. Administer via **slow intravenous injection or infusion**.
3. Use under the supervision of a healthcare professional.

Dosage and Administration:

1. **Adult Dose:** 40 mg once daily IV.
2. In severe conditions, dose may be increased as per physician's advice.
3. Administer over 2–15 minutes or diluted in infusion fluid over 15–30 minutes.

Safety Information:

1. For hospital/clinical use only.
2. Use with caution in hepatic impairment.
3. Monitor for prolonged suppression in long-term use.
4. Do not co-administer with atazanavir or rilpivirine.

Mechanism of Action:

- Pantoprazole blocks the final step of gastric acid production by inhibiting the H⁺/K⁺ ATPase enzyme system at the surface of gastric parietal cells, leading to significant and sustained acid reduction.

Contraindications:

1. Known hypersensitivity to pantoprazole or substituted benzimidazoles.
2. Caution in patients with severe liver disease.

Side Effects:

1. Headache, diarrhea, nausea.
2. Injection site reactions.
3. Rare: Hypomagnesemia, B12 deficiency with prolonged use.

Important Notice:

- Administer only under medical supervision.
- Not for long-term use unless prescribed.
- Ensure complete dosage as advised for full therapeutic benefit.

Storage Condition:

1. Store below 25°C.
2. Protect from light and moisture.
3. Reconstituted solution should be used immediately.
4. Keep out of reach of children.

Packing Information:

- Pantoprazole 40 mg injection Vial+ Wfi.
- Sterile vial.

